Neofunction of ACVR1 in fibrodysplasia ossificans progressiva

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15438-15443

  Hino, Kyosuke ^a,b   Ikeya, Makoto ^a   Horigome, Kazuhiko ^a,b   Matsumoto, Yoshihisa ^a,c,d   Ebise, Hayao ^b   Nishio, Megumi ^a   Sekiguchi, Kazuya ^a,c,e   Shibata, Mitsuaki ^a   Nagata, Sanae ^a   Matsuda, Shuichi ^e   Toguchid, Junya ^a,c,e  

^a KYOTO UNIVERSITY   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

BMP; Fibrodysplasia ossificans progressiva; Heterotopic ossification; IPSC; TG

Indexed keywords

ACTIVIN A; ACVR1 PROTEIN; BONE MORPHOGENETIC PROTEIN; PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIFICATION; CARTILAGE CELL; CHONDROGENESIS; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RARE DISEASE; SIGNAL TRANSDUCTION; BONE MINERALIZATION; DRUG EFFECTS; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; OSSIFYING MYOSITIS; PATHOLOGY; PATHOPHYSIOLOGY;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; BONE MORPHOGENETIC PROTEINS; CALCIFICATION, PHYSIOLOGIC; CHONDROGENESIS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOSITIS OSSIFICANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84950327119     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510540112     Document Type: Article

References (44)

1. Kaplan F, et al. (2005) The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3(3-4):183-188.
2. Shore E, Feldman G, Xu M, Kaplan F (2005) The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3(3-4):201-204.
3. Kaplan FS, Groppe J, Pignolo RJ, Shore EM (2007) Morphogen receptor genes and metamorphogenes: Skeleton keys to metamorphosis. Ann N Y Acad Sci 1116:113-133.
4. Kaplan FS, et al. (2008) Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22(1):191-205.
5. Shore EM, Kaplan FS (2010) Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol 6(9):518-527.
6. Kaplan FS, Chakkalakal SA, Shore EM (2012) Fibrodysplasia ossificans progressiva: Mechanisms and models of skeletal metamorphosis. Dis Model Mech 5(6):756-762.
7. Shore EM, et al. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525-527.
8. Urist MR (1965) Bone: Formation by autoinduction. Science 150(3698):893-899.
9. Wozney JM, et al. (1988) Novel regulators of bone formation: Molecular clones and activities. Science 242(4885):1528-1534.
10. Mueller TD, Nickel J (2012) Promiscuity and specificity in BMP receptor activation. FEBS Lett 586(14):1846-1859.
11. Kaplan FS, et al. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30(3):379-390.
12. Chaikuad A, et al. (2012) Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287(44):36990-36998.
13. Fukuda T, et al. (2008) A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 377(3):905-909.
14. Fukuda T, et al. (2009) Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 284(11):7149-7156.
15. Shen Q, et al. (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 119(11):3462-3472.
16. Song GA, et al. (2010) Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 285(29):22542-22553.
17. van Dinther M, et al. (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25(6):1208-1215.
18. Ohte S, et al. (2011) A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem Biophys Res Commun 407(1):213-218.
19. Le VQ, Wharton KA (2012) Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Dev Dyn 241(1):200-214.
20. Bagarova J, et al. (2013) Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol 33(12):2413-2424.
21. Chakkalakal SA, et al. (2012) An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 27(8):1746-1756.
22. Culbert AL, et al. (2014) Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification. Stem Cells 32(5):1289-1300.
23. Billings PC, et al. (2008) Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 23(3):305-313.
24. Hamasaki M, et al. (2012) Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: Mechanisms of reprogramming and strategy for drug identification. Stem Cells 30(11):2437-2449.
25. Matsumoto Y, et al. (2013) Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis 8:190.
26. Matsumoto Y, et al. (2015) New protocol to optimize iPS cells for genome analysis of fibrodysplasia ossificans progressiva. Stem Cells 33(6):1730-1742.
27. Hogan BL (1996) Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 10(13):1580-1594.
28. Gu Z, et al. (1999) The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development 126(11):2551-2561.
29. Mishina Y, Crombie R, Bradley A, Behringer RR (1999) Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. Dev Biol 213(2):314-326.
30. Massagué J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295-309.
31. Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein receptors and signal transduction. J Biochem 147(1):35-51.
32. Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13(15):2105-2124.
33. Canalis E, Economides AN, Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24(2):218-235.
34. Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J (2007) Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of Activin to its type II receptor. J Endocrinol 195(1):95-103.
35. Phillips DJ, de Kretser DM, Hedger MP (2009) Activin and related proteins in inflammation: Not just interested bystanders. Cytokine Growth Factor Rev 20(2):153-164.
36. Antsiferova M, Werner S (2012) The bright and the dark sides of Activin in wound healing and cancer. J Cell Sci 125(Pt 17):3929-3937.
37. Groppe JC, Wu J, Shore EM, Kaplan FS (2011) In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194(2-4):291-295.
38. Martin B, et al. (1992) Selective synthetic ligands for human nuclear retinoic acid receptors. Skin Pharmacol 5(1):57-65.
39. Shimono K, et al. (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med 17(4):454-460.
40. Zuscik MJ, Hilton MJ, Zhang X, Chen D, O'Keefe RJ (2008) Regulation of chondrogenesis and chondrocyte differentiation by stress. J Clin Invest 118(2):429-438.
41. Hatsell SJ, et al. (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to Activin A. Sci Transl Med 7(303):303ra137.
42. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM (1998) The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1(5):673-683.
43. Fukuta M, et al. (2014) Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. PLoS One 9(12):e112291.
44. Yokoyama K, et al. (2015) Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. Arthritis Rheumatol 67(1):302-314.